

FINAL WEEKS
to Register


12th ANNUAL

MAY 31 - JUNE 1, 2017
PARK CENTRAL HOTEL | SAN FRANCISCO, CA

NEUROTECH

Investing & Partnering Conference

Discover emerging drugs, devices, diagnostics and software
for the brain and nervous system



COVERAGE INCLUDES

- Alzheimer's and Cognitive Disorders
- Pain and Epilepsy
- CNS Drug and Device Development
- Parkinson's and Movement Disorders
- Next-Generation Psychiatry
- Neurotherapeutic Nutrition
- Orphan Diseases
- Multiple Sclerosis
- Emerging Companies

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!

NEUROTECHpartnering.com

PREMIER SPONSOR



neuroscience trials australia

PARTNERS



NEUROINSIGHTS



A Division of Cambridge Innovation Institute

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!
NEUROTECHpartnering.com

The neurotechnology sector holds promise to deliver treatments for CNS disorders for which the unmet need is high. Over the last decade, significant advances have taken place in this field, driven by venture investment and strategic partnerships. Now in its 12th year, the **Neurotech Investing and Partnering Conference** is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software, and diagnostics for the brain and nervous system.

This global forum brings together investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system to shape the future of their organization and the industry. Featuring keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects, and dynamic panel discussions, Neurotech Investing and Partnering spans a comprehensive selection of current neurotech topics.

Facilitated networking opportunities and partnering tools provide an ideal venue to connect investors with potential partners, and launch the new relationships that will grow into tomorrow's successful treatments and partnerships.

Organized by the Neurotechnology Industry Organization and new partner Cambridge Healthtech Institute, this year's event promises to continue a tradition of carefully curated, high quality content and invaluable networking. We hope to see you in San Francisco!

Alison Fenney, MBA, Ph.D.
Executive Director
Neurotechnology Industry Organization (NIO)


PREMIER SPONSOR



CORPORATE SPONSOR



CORPORATE SUPPORT SPONSOR



- CEO 36%
- Manager/Director 21%
- Other 11%
- VP 10%
- Managing Partner 7%
- President 6%
- Business Development 4%
- Scientist 3%
- Professor 2%

NeuroInsights

www.neuroinsights.com



For over a decade, NeuroInsights has been helping entrepreneurs, executives, investors, and governments understand and profit from the growth of drugs, devices and diagnostics for the brain and nervous system.

We achieve this through a broad range of strategic business advisory services, in-depth market and industry investment reports, Neurotech Insights - our monthly industry newsletter covering financing and product news, and our flagship neurotech investing and partnering conferences.

NeuroInsights will enable you to track market dynamics, develop investment strategies, identify partnering opportunities, and analyze comparables across this \$160 billion global industry.

Neurotechnology Industry Organization (NIO)

www.neurotechindustry.org



Since 2006, over 120 neuroscience organizations have joined the Neurotechnology Industry Organization in our mission to accelerate neurotechnology research, development and commercialization, including neuroscience companies, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. NIO's programs have the following goals: advocate the industry's position to regulators and elected officials; inform the media about industry's progress and contributions to quality of life; provide industry events and business development services to the industry; foster leadership positions that drive innovation forward.

Cambridge Healthtech Institute

www.healthtech.com



Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular

Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, Next Generation Dx Summit and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.



A Division of Cambridge Innovation Institute

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!
NEUROTECHpartnering.com

7:30am Conference Registration and Continental Breakfast

8:30 Welcome Keynote and State of Neurotech Industry 2017

Alison Fenney, Executive Director, Neurotechnology Industry Organization
Harry Tracy, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports

9:00 Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Josh Pinto, Vice President Healthcare Investment Banking, Credit Suisse

Panelists:

Andy Schwab, Managing Partner, 5AM Ventures
Joseph Sum, Analyst, EcoR1 Capital
Ilan Zipkin, Senior Investment Director, Takeda Venture Partners
Heath Lukatch, Partner and Managing Director, TPG Biotech

10:00 Coffee Break in the Exhibit Hall

10:40 Treatments for Alzheimer's and Cognitive Disorders

Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?

Moderator: Michael W. Weiner, M.D. Principal Investigator, Alzheimer's Disease Neuroimaging Initiative and Professor, UCSF School of Medicine

Panelists:

Casey Lynch, CEO, Cortexyme
Joe Collard, Chief Business Officer, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix
John Didsbury, Founder & CEO, T3D Therapeutics

11:40 Developments on the Horizon for Pain and Epilepsy

Ongoing research is revealing new pharmaceutical and device options to treat pain and epilepsy. Novel therapeutic modalities aim to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. What are the novel devices in this space? How are side effects being addressed?

Moderator: Garth Smith, Director, Industry Relations, Ontario Brain Institute

Panelists:

Alex Ni, CTO, Avertus
Conrado Pascual, Scientist, AfaSci Research Laboratories
Christopher C. Gallen, M.D., Ph.D., CEO, WEX Pharmaceuticals
Ashish Khanna, Chief Business Officer, Aptinyx

12:40pm Networking Luncheon

1:55 Internal and External Research & Development

Big pharma, big medtech and large biotech companies collaborate with smaller companies and academic institutions on a variety of projects. How can opportunities be spotted? What are current areas of interest? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?

Moderator: Jay Kranzler, CEO, Regenovation

Panelists:

Ryan Westphal, Director, Search and Evaluation, Neuroscience, Eli Lilly and Company
Anne Pianca, Director, R&D Neuromodulation, Boston Scientific
Widya Mulyasmita, Ph.D., Manager, New Ventures Johnson & Johnson Innovation
Kerry Mahon, Partnerships and Business Development, Verily

2:55 Refreshment Break in the Exhibit Hall *Sponsored by*  *neuroscience trials australia*

3:35 Strategies in CNS Drug and Device Development

Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Moderator: Carla Lema Tome, Advisor, Neurotechnology Industry Organization

Panelists:

Tina Soulis, General Manager, Neuroscience Trials Australia
Lovingly Park, Director, Scientific Affairs, PAREXEL
Joseph Araujo, President and CEO, Intervivo
Stephanie Fertig, MBA, Director, NINDS Small Business Programs, National Institute of Neurological Disorders and Stroke, National Institutes of Health

4:35 Emerging Company Showcase (View Website for Details)

5:35 Welcome Reception in the Exhibit Hall

6:30 Close of Day

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!
NEUROTECHpartnering.com

7:30am Conference Registration and Continental Breakfast

8:30 Licensing and Acquisitions in Neurotech

Neurology is projected to be medtech's fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. Overall, big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and in licensing? What are priority indications and requirements for licensing deals? Which companies are active in deal-making?

Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises

Panelists:

*Jeff Calcagno, New Ventures, Johnson & Johnson Innovation
Murali Gopalakrishnan, Senior Director, Head, Search & Evaluation Neuroscience, AbbVie
Carrie Cook, Senior Director, R&D Business Development, Takeda
Steven Bartz, Director, Business Development & Licensing, Merck*

9:30 Parkinson's and Other Movement Disorders

Current treatments for movement disorders can improve functioning but suffer from side effects and "off" periods especially as the disease progresses. What are the latest advances in movement disorders? What is in the pipeline to address side effects and other issues specific to this class? Can disease modifying treatments alter the course of disease? Can diagnostics improve treatment?

Moderator: John Reppas, Director of Public Policy, Neurotechnology Industry Organization

Panelists:

*Kyle Gano, Vice President Business Development, Neurocrine Biosciences
Judith Kelleher-Andersson, President and CEO, Neuronascent
John Hoekman, Interim CEO and CoFounder, Impel NeuroPharma
Daniel Adams, CSO, PhotoPharmics
Timothy Still, President and CEO, Global Kinetics Corporation*

10:30 Coffee Break in the Exhibit Hall

11:15 Next-Generation Psychiatry

Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next-generation treatments? How will devices and diagnostics change the treatment landscape?

Moderator: Manuel Lopez Figueroa, Partner, Bay City Capital

Panelists:

*Robert Linke, President & CEO, Embera NeuroTherapeutics
Brad Margus, CEO, Cerevance
Greg Vontz, CEO, BlackThorn Therapeutics
David Baker, Chief Commercial Officer, Alcobra Inc*

12:15pm Networking Luncheon

1:30 Frontiers in Neurotechnology

In this session we will hear from companies on the cutting edge. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Which are the most exciting next-generation products and companies? How are they addressing unmet needs in neurotech?

Moderator: Imran Eba, Partner, Action Potential Venture Capital, GSK

Panelists:

*Corinna Lathan, CEO, Anthrotronix
Melanie McWade, Vice President, Emerging Therapies, Nexeon Medsystems
Robert Hamilton, CEO, Neural Analytics
Patrick Tompkins, Executive Vice President, Sales, Stimwave Technologies*

2:30 Therapeutic Nutrition in CNS

Nutrition is at the core of novel approaches for disease prevention and treatment, from neurodevelopment to neurodegeneration. Advances in the understanding of the biological effects of nutrients, enzyme activity and bidirectional communication between the central nervous system and the gut have illuminated new opportunities in drug development for CNS disorders. What companies are exploring these approaches? What challenges will companies face in developing, clinically validating and bringing these treatments to market?

Moderator: Charles Stacey, CEO, Accera

Panelist:

*John Andrews, CEO, Ketogen/NAMENA
Joan Fallon, CEO, Curemark
David H. Donabedian, Co-founder & CEO, Axial Biotherapeutics*

3:30 Networking Refreshment Break

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!
NEUROTECHpartnering.com

3:45 Targeting Orphan Diseases

Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. Hear from companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more. What are the strategies to succeed in addressing a smaller market? Are R&D approaches different than for other indications?

Moderator: Sara Shnider, Senior Manager, Academic Affairs and Networks, Teva Pharmaceuticals

Panelists:

Tim Miller, CEO, Abeona Therapeutics

Alice Zhang, CEO & Co-founder, Verge Genomics

Lisa McKerracher, CEO, BioAxone bioSciences Inc.

4:45 New Strategies in Multiple Sclerosis

Therapies directed at novel targets, more specific immune modulators and trophic factors are in development for multiple sclerosis. What are the promising treatments in development? How are indication-specific hurdles being addressed? What novel approaches are being pursued?

Moderator: Edward Spack, Managing Director, Fast Forward LLC, National Multiple Sclerosis Society

Panelists:

Marie Wesselhoft, President and Co-Founder, MSDx

Carlos Buesa, CEO, Oryzon

Travis L. Stiles, CEO, Novoron Bioscience

5:45 Close of Conference

4th INTERNATIONAL EUROPEAN

NEUROTECH

Investing & Partnering Conference

3 - 4 OCTOBER 2017 | GENEVA, SWITZERLAND

Unable to join us in the US? Please join us in Europe!

NEUROTECHpartneringeurope.com

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!

NEUROTECHpartnering.com

SPONSORSHIP & EXHIBIT INFORMATION

Why Sponsor at Neurotech 2017?

Neurotech 2017 provides the best opportunity for exhibitors to promote their products, services and publications to leading decision makers, executives, and scientists in commercial neuroscience.

- Establish new customer leads
- Demonstrate products/services to a diverse group of leading companies
- Maintain a market presence
- Gain recognition with emerging neuropharma and neurodevice companies, key specialty companies, investors, big pharma, major medical device companies and the media

Promotion of the 12th Annual Event

Outreach and marketing will be conducted regularly from November 2016 to May 2017 including at other events, via mail and email and social media.

Direct marketing efforts including mailers and email highlighting the conference and its sponsors are targeted to opt in lists of 20,000 people.

- The Neurotechnology Industry Organization will be promoting the conference and its sponsors in collaboration with NeuroInsights at conferences throughout the fall, winter and spring.
- Promotion in collaboration with partner organizations including Biospace, Genetic Engineering & Biotechnology News and The Scientist and others.

Premier Sponsor/Presentation \$25,000

- 15 minute presentation to all session attendees as part of the main conference program or relevant panel
- Eight (8) main conference registrations including speaker (excludes short courses and symposia)
- 1 copy of The Neurotechnology Industry 2016-2017 Report
- Sponsor logo will be highlighted as sponsoring lunch or cocktail hour
- Distribution of marketing materials to attendees at a display table
- Sponsor will create an advertising page for conference booklet
- One 8'x10' exhibit space
- Corporate logo inside the final conference brochure PDF
- Corporate logo on the conference proceedings
- Additional full conference registrations available at a discount for your staff (Limited to 5)
- Corporate logo with link on the event website
- 50-word company description in the Program & Exhibits Guide
- On-site signage designating your company as a corporate sponsor
- One-time use of delegate list – for one pre and one post-show physical mailing
- Cooperative promotional email to your list of customers/prospects promoting your presence at the event and offering them a discount to attend

Corporate Sponsor \$20,000

- Six (6) main conference registrations (excludes short courses and symposia)
- 1 copy of The Neurotechnology Industry 2016-2017 Report
- Sponsor logo will be highlighted as sponsoring lunch or cocktail hour
- Distribution of marketing materials to attendees at a display table
- Sponsor will create an advertising page for conference booklet
- One 8'x10' exhibit space
- Corporate logo inside the final conference brochure PDF
- Corporate logo on the conference proceedings
- Additional full conference registrations available at a discount for your staff (Limited to 5)
- Corporate logo with link on the event website
- 50-word company description in the Program & Exhibits Guide
- On-site signage designating your company as a corporate sponsor
- One-time use of delegate list – for one pre and one post-show physical mailing
- Cooperative promotional email to your list of customers/prospects promoting your presence at the event and offering them a discount to attend

Corporate Support Sponsor \$10,000

- Four (4) main conference registrations (excludes short courses and symposia)
- Sponsor logo will be highlighted as sponsoring lunch or cocktail hour
- Distribution of marketing materials to attendees at a display table
- Sponsor will create an advertising page for conference booklet
- One 8'x10' exhibit space
- Corporate logo inside the final conference brochure PDF
- Corporate logo on the conference proceedings
- Additional full conference registrations available at a discount for your staff (Limited to 5)
- Corporate logo with link on the event website
- 50-word company description in the Program & Exhibits Guide
- On-site signage designating your company as a corporate sponsor
- One-time use of delegate list – for one pre and one post-show physical mailing
- Cooperative promotional email to your list of customers/prospects promoting your presence at the event and offering them a discount to attend

EXHIBIT BOOTH SPACE - \$4,195

Exhibitors will enjoy facilitated networking opportunities with all conference delegates, making it the perfect platform to launch a new product, collect feedback, and generate new leads. Exhibit space sells out quickly, so reserve yours today.

For more information on sponsorship and exhibit opportunities, please contact:

Angela Parsons, VP Business Development | 781.972.5467 | aparsons@healthtech.com

FINAL WEEKS
to Register

How to Register: **NEUROTECHpartnering.com**

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode
CNP F
when registering!

Cover

Welcome

Attendee Demographics

AGENDA

Sponsor & Exhibit Information

Hotel & Travel Information

Registration Information

Register Online!
NEUROTECHpartnering.com

Pricing and Registration Information

EVENT PRICING

	Academic, Government, Hospital-affiliated	Commercial	NIO Members
Advance Registration Discount until May 5, 2017	\$1795	\$2095	\$1675
Registrations after May 5, 2017, and on-site	\$1995	\$2295	\$1835

EVENT DISCOUNTS

REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Group Discounts: Discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472.

ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link. Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetails

Video and/or audio recording of any kind is prohibited onsite at all CHI events.

The premier
partnering and investing conference
for the neurotechnology industry, spanning
pharmaceuticals, medical devices, software and diagnostics
for the brain and nervous system

HOTEL & TRAVEL INFORMATION

Conference Hotel and Venue:

Park Central Hotel San Francisco, A Starwood Hotel
50 Third Street
San Francisco, CA 94103
Phone: 415-974-6400

Reservations: Go to the hotel and venue page of NEUROTECHpartnering.com

Discounted Room Rate: \$239 s/d

Discounted Cut-off Date: May 1, 2017

Go to the hotel and venue page of NEUROTECHpartnering.com for additional info



A Division of Cambridge Innovation Institute

NEUROTECHpartnering.com | 7